Kathleen Glick

550 total citations · 1 hit paper
9 papers, 377 citations indexed

About

Kathleen Glick is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Kathleen Glick has authored 9 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Hematology, 5 papers in Molecular Biology and 3 papers in Oncology. Recurrent topics in Kathleen Glick's work include Acute Myeloid Leukemia Research (8 papers), Cancer therapeutics and mechanisms (3 papers) and Acute Lymphoblastic Leukemia research (3 papers). Kathleen Glick is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Cancer therapeutics and mechanisms (3 papers) and Acute Lymphoblastic Leukemia research (3 papers). Kathleen Glick collaborates with scholars based in United States, Canada and Argentina. Kathleen Glick's co-authors include Franklin O. Smith, Alan S. Gamis, Soheil Meshinchi, Susana C. Raimondi, Robert B. Gerbing, Laura Winter, Todd A. Alonzo, Amy Heerema‐McKenney, Samir B. Kahwash and Richard Aplenc and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Pediatric Blood & Cancer.

In The Last Decade

Kathleen Glick

9 papers receiving 370 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

2014 313 citations Alan S. Gamis, Todd A. Alonzo et al. Journal of Clinical Oncology profile →

Peers

Kathleen Glick

HEMAT

PHEOH

ONCOL

MB

PPCH

Patti Byron United States

MD Amylon United States

Manon Queudeville Germany

Edward Kwan Australia

Sajad Khazal United States

Masanobu Kasai Japan

Parveen Shiraz United States

Jared Becksfort United States

Eleonora Toffoletti Italy

Michael Starck Germany

Patti Byron United States

Kathleen Glick

263 ×0.9

HEMAT

147 ×0.9

PHEOH

129 ×1.0

ONCOL

112 ×1.0

MB

43 ×1.0

PPCH

Citations per year, relative to Kathleen Glick Kathleen Glick (= 1×) peers Patti Byron

Countries citing papers authored by Kathleen Glick

Since Specialization

Citations

This map shows the geographic impact of Kathleen Glick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathleen Glick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathleen Glick more than expected).

Fields of papers citing papers by Kathleen Glick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathleen Glick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathleen Glick. The network helps show where Kathleen Glick may publish in the future.

Co-authorship network of co-authors of Kathleen Glick

This figure shows the co-authorship network connecting the top 25 collaborators of Kathleen Glick. A scholar is included among the top collaborators of Kathleen Glick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathleen Glick. Kathleen Glick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Weiss, Aaron R., Sarah Dry, Christine W. Lary, et al.. (2023). A pilot study evaluating the use of sirolimus in children and young adults with desmoid‐type fibromatosis. Pediatric Blood & Cancer. 70(9). e30466–e30466. 2 indexed citations

2.

Gamis, Alan S., Todd A. Alonzo, Soheil Meshinchi, et al.. (2014). Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. Journal of Clinical Oncology. 32(27). 3021–3032. 313 indexed citations breakdown →

3.

Gamis, Alan S., Richard Aplenc, Todd A. Alonzo, et al.. (2013). Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531. Blood. 122(21). 355–355. 11 indexed citations

4.

Alonzo, Todd A., Robert B. Gerbing, Samir B. Kahwash, et al.. (2013). Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report. Blood. 122(21). 612–612. 9 indexed citations

5.

Loken, Michael R., Todd A. Alonzo, Laura Pardo, et al.. (2011). Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531. Blood. 118(21). 939–939. 5 indexed citations

6.

Gamis, Alan S., Todd A. Alonzo, Robert B. Gerbing, et al.. (2010). Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531. Blood. 116(21). 182–182. 11 indexed citations

7.

Sung, Lillian, Todd A. Alonzo, Robert B. Gerbing, et al.. (2010). High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.. Blood. 116(21). 1072–1072. 1 indexed citations

8.

Sung, Lillian, Richard Aplenc, Todd A. Alonzo, et al.. (2010). Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.. Blood. 116(21). 1071–1071. 9 indexed citations

9.

Franklin, Janet, Todd A. Alonzo, Craig A. Hurwitz, et al.. (2008). COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML). Blood. 112(11). 136–136. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact